KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
Kymera Therapeutics has announced positive results from its trial of KT-621 to treat patients with moderate to severe atopic ...
As the body’s first line of defense, the skin performs multiple vital functions—it safeguards internal organs, regulates body ...
The FDA’s approval of Waskyra marks a historic breakthrough in treating Wiskott–Aldrich syndrome, a rare and life-threatening ...
On top of the rapid rise in flu, hospitals are also seeing a 35% increase in norovirus patients, prompting warnings that ...
“Eating at least five portions of fruit and vegetables so that you are getting enough of key vitamins including vitamin A, C ...
[GET] "/_nuxt/builds/meta/cfffaac4-3d35-4a20-a820-edaba6d23eb4.json": 403 Forbidden ...
Children a more prone to infections in colder months. Here are tips for parents to keep in mind, and red flags to watch out ...
Financing funds the global Phase 2b clinical trial in atopic dermatitis and Phase 2 clinical program in molluscum ...
You can use FSA funds on more than just medical procedures and copays. Here's how to save on medication, period products, glasses, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback